MedTrace Logo

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2013-02-04

No results posted yet for this study

Summary

This study is designed to assess the use of pramipexole dihydrochloride and quetiapine (Seroquel) XR as combination therapy for bipolar depression. The proposed benefit of the combination therapy investigated in this study is improved treatment of bipolar depression.

Conditions

Interventions

DRUG

quetiapine (Seroquel) XR

tablets and caplets, take with liquid before bedtime

DRUG

quetiapine (Seroquel) XR

tablets, take with liquid before bedtime

DRUG

placebo

placebo

DRUG

pramipexole dihydrochloride

tablets and caplets, take with liquid before bedtime

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00893841 on ClinicalTrials.gov